ASC41 + itraconazole

ASC41 + itraconazole is a combination of two drugs: - **ASC41** is a liver-targeted small molecule prodrug whose active metabolite, ASC41-A, is a selective **thyroid hormone receptor beta (THRβ) agonist**. ASC41 is being developed primarily for the treatment of **non-alcoholic steatohepatitis (NASH)/metabolic dysfunction–associated steatohepatitis (MASH)** and has shown significant reduction in liver fat and improvement in lipid parameters in early-phase clinical studies. - **Itraconazole** is a triazole **antifungal** medication used to treat serious systemic and superficial fungal infections (such as aspergillosis, blastomycosis, histoplasmosis, and onychomycosis). It acts by inhibiting fungal 14α-demethylase, blocking ergosterol synthesis, a crucial component of the fungal cell membrane. This combination is not a standard or approved therapy but might be studied for drug interaction, pharmacokinetic, or safety reasons (especially as ASC41 is metabolized by CYP3A4, which is inhibited by itraconazole)[1][3][5][4].

Other names

ASC41-A (active metabolite)ITZ (abbreviation for itraconazole)